# Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

> **NCT00250874** · PHASE2 · UNKNOWN · sponsor: **Zeneus Pharma** · enrollment: 45 (—)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab

## Key facts

- **NCT ID:** NCT00250874
- **Lead sponsor:** Zeneus Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 45 (—)
- **Last updated:** 2005-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250874, "Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00250874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*